Sanmina Corporation announced it will host its Q4 and full fiscal year 2026 earnings conference call on November 9, 2026, at 5:00 PM ET. Investors can access the live webcast and supporting materials on Sanmina's website, with a replay available after the event. As a Fortune 500 company, Sanmina is a key player in the Electronics Manufacturing Services market, providing manufacturing solutions to various industries including industrial, medical, aerospace, automotive, and AI infrastructure. This earnings call will provide insights into the company's recent performance and future outlook.
Sanmina Corporation's upcoming Q4 and fiscal year 2026 earnings call is scheduled for November 9, 2026. For readers following the Technology sector, here is Pluang's market snapshot as of Oct 20, 2026 03:01 WIB: out of 150 priced US stocks, 81 rose and 67 fell. Notable movers include DigitalOcean Holdings Inc at USD 97.94 with a -10.53% change, Fastly Inc at USD 22.45 with a -10.45% change, and GoPro Inc at USD 1.03 with a -10.43% change.
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
